Replies to post #3176 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT builds $230M manufacturing plant in Jiaxing, China:

http://finance.yahoo.com/news/Abbott-Expanding-prnews-2972732213.html?x=0&.v=1

The facility represents Abbott's largest investment in China to date and will manufacture premium powdered milk products for Chinese infants and children.

More than 17 million infants are born each year in China and rising incomes and a growing middle class have created increased demand for high-quality nutrition products. To meet the needs of this dynamic market, Abbott anticipates launching a number of new product innovations over the next three years across the pediatric nutrition category in China.

… With the addition of the new facility in Jiaxing, Abbott will have opened six manufacturing and R&D facilities in its nutrition and pharmaceuticals businesses in the Asia-Pacific region during the past three years, including three in China.

China represents the largest single market growth opportunity in global nutrition. Abbott expects to increase its nutrition revenues in China to more than $1 billion (USD) by the end of 2014. China also continues to be an important part of Abbott's emerging markets strategy. In the first half of the year, more than 26 percent of Abbott's global sales were in emerging markets and nearly 42 percent of Abbott Nutrition's global sales were in emerging markets [#msg-65469700].

[DewDiligence]

ABT spinoff factoids re The Global Demographic Tailwind:

• The diversified products successor company (the one that will continue to be called Abbott) will derive 47% of sales from emerging markets in 2014, up from 39% currently.

• ABT’s nutritionals business, which comprises about a quarter of the diversified products successor company, will have $1B of sales in China alone by 2014.

Source: http://media.corporate-ir.net/media_files/irol/94/94004/presentations/Abbott_Investor_Day_2011.pdf

For (unflattering) commentary on ABT’s planed split-up, see #msg-68135262.